RxSight, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ronald Kurtz
- Full Time Employees
- 498
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 100 Columbia Aliso Viejo CA United States of America 92656
- IPO Date
- Jul 30, 2021
- CIK
- 0001111485
- Website
- rxsight.com
- Similar Companies
- Business
- RxSight, Inc. (Nasdaq: RXST) develops, manufactures and commercializes light adjustable intraocular lenses and related equipment for customized vision correction in cataract surgery patients; its proprietary RxSight system comprises the RxSight Light Adjustable Lens (LAL) and LAL+, photosensitive intraocular lenses that enable post-operative adjustments via ultraviolet light to optimize uncorrected visual acuity and correct low levels of astigmatism as low as 0.50 diopters; the RxSight Light Delivery Device (LDD), an office-based treatment console that delivers programmed UV light patterns to modify the LAL; and the RxSight Planner software for treatment planning. The company targets ophthalmologists and cataract surgeons serving premium intraocular lens (IOL) markets, primarily in the United States where it holds FDA approval and maintains an installed base exceeding 1,000 LDDs; it operates from headquarters in Aliso Viejo, California, founded in 1997 as Calhoun Vision, Inc. and renamed RxSight in February 2017. In recent developments, RxSight realigns its U.S. commercial organization by integrating clinical and sales teams to enhance LAL practice integration and launches new practice development programs leveraging insights from over 250,000 LAL cases; it enters international markets including South Korea and Singapore in 2025 while planning further expansion into Asia and Europe; preliminary 2024 results show full-year revenue of $139.9 million with 79% LAL procedure growth and issues 2025 revenue guidance of $185-$197 million alongside gross margin expansion to 71-73%.
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
Did RxSight, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
RxSight, Inc. (RXST) Presents at Bank of America Global Healthcare Conference 2026 Transcript
RxSight, Inc. (RXST) Q1 2026 Earnings Call Transcript
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook
RxSight, Inc. to Present at the Bank of America Healthcare Conference
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026
RxSight (NASDAQ:RXST) Trading Down 3.7% – Time to Sell?
RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference
RxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of “Reduce” by Analysts
Short Interest in RxSight, Inc. (NASDAQ:RXST) Expands By 29.3%
RxSight, Inc. (RXST) Q4 2025 Earnings Call Transcript
RxSight, Inc. (RXST) Reports Q4 Loss, Beats Revenue Estimates
Earnings Preview: RxSight, Inc. (RXST) Q4 Earnings Expected to Decline